omniture
和铂医药(上海)有限公司 Harbour BioMed

Latest News

Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics

CAMBRIDGE, Mass., Feb. 10, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM ...

2023-02-10 13:00 2566

HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders

CAMBRIDGE, Mass., Jan. 26, 2023 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative...

2023-01-26 09:22 3511

Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics

CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM ...

2022-11-21 17:31 3199

Nona Biosciences Announces Attendance at PEGS Europe 2022

CAMBRIDGE, Mass., Nov. 15, 2022 /PRNewswire/ -- Nona Biosciences (a wholly-owned subsidiary of HBM ...

2022-11-15 15:57 2626

HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Harbor Bi...

2022-11-15 12:19 2328

Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Harbour B...

2022-11-11 09:03 2961

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

CAMBRIDGE, Mass., ROTTERDAM and SUZHOU, China, Oct. 20, 2022 /PRNewswire/ -- Harbour BioMed ("HBM",...

2022-10-20 16:20 2174

Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour B...

2022-10-13 19:05 1865

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Harbour ...

2022-09-27 21:40 1771

Harbour BioMed to Announce 2022 Interim Results on August 31, 2022

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Harbour Bi...

2022-08-09 15:00 2173

PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Harbour Bi...

2022-08-08 17:43 2334

Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 27, 2022 /PRNewswire/ -- Harbour B...

2022-06-27 19:04 2819

Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 8, 2022 /PRNewswire/ --Harbour ...

2022-06-08 18:11 1981

Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Harbour...

2022-06-01 21:24 2965

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 25, 2022 /PRNewswire/ -- Harbour...

2022-05-25 17:42 2692

Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 10, 2022 /PRNewswire/ -- Harbour...

2022-05-10 16:54 3098

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ -- Harbour ...

2022-05-06 08:00 2466

Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2022 /PRNewswire/ -- Harbour ...

2022-04-14 08:46 2025

Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbou...

2022-04-07 09:09 2182

Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbour B...

2022-04-06 15:04 2881